Microbix announces new flu vax subsidiary

Toronto-based Microbix Biosystems has created a subsidiary to support its flu vaccine business, including a deal with China's Hunan Biopharmaceutical. The new company, Crucible International Biotechnologies, is valued at C$14 million, which will help finance a new production building.

Microbix will also transfer its Virusmax production technology to Crucible, which should double vaccine production. In 2008, the company entered an agreement with Hunan to create the world's third largest vaccine production facility, capable of creating 120 million doses each year.

- check out Reuters' story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.